City of Hope National Medical Center received $7.5 million in federal and private grants to study a rare blood cancer that affects the skin.
The National Cancer Institute awarded two grants valued at $6.3 million over five years to researchers Dr. Steven Rosen and Dr. Christiane Querfeld at the Duarte hospital to develop treatments for cutaneous T cell lymphoma (CTCL), an incurable cancer.
The Leukemia & Lymphona Society kicked in another $1.2 million to study a disfiguring disease that impacts 3,000 new patients a year.
The researchers will work in two laboratories to develop drugs that could treat a skin lymphoma that can result in large disfiguring plaques and tumors on the skin, or a red rash that can cover the entire body.
“The goal Dr. Rosen and I have in our respective labs is to develop life-changing treatments for people who have CTCL,” said Querfeld, in a statement.
Conventional treatments for CTCL only work for a few months, hospital officials say, with less than a third of patients who respond to treatment.
Health business reporter Dana Bartholomew can be reached at firstname.lastname@example.org. Follow him on Twitter @_DanaBart.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- City of Hope Receives $12.5 Million Federal Grant to Fight Lymphoma
- PeproMene Bio Receives $40 Million
- Kite Wins Approval to Sell Blood Cancer Treatment in the U.K.
- UCLA and City of Hope Receive $2.8 Million in Grants for Stem Cell Research
- Children’s Hospital L.A. Awarded $9M to Study ‘Bubble Boy’ Syndrome
- Children’s Hospital Los Angeles Receives $1.2 Million to Study Drug Resistance in Leukemia
- UCLA Receives $5M Federal Grant to Study Early Lung Cancer Detection
- City of Hope Lands Nearly $6M Grant for Stem Cell Study for Sickle Cell Disease